{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/irritable-bowel-syndrome/prescribing-information/antidepressant-drugs/","result":{"pageContext":{"chapter":{"id":"b5eff265-676e-584f-a5d6-0a4714238d8f","slug":"antidepressant-drugs","fullItemName":"Antidepressant drugs","depth":2,"htmlHeader":"<!-- begin field d0de33f5-33c2-4efd-ae54-dd14f5de7c96 --><h2>Antidepressant drugs</h2><!-- end field d0de33f5-33c2-4efd-ae54-dd14f5de7c96 -->","summary":"","htmlStringContent":"<!-- begin item 1ec4edc6-6442-4846-b914-44faea628178 --><!-- begin field 612e617f-3888-4753-8300-a800010645b9 --><ul><li><strong>Tricyclic antidepressants (TCAs) such as amitriptyline,</strong> may be used for the management of pain associated with irritable bowel syndrome (off-label indication).<ul><li>The National Institute for Health and Care Excellence (NICE) recommends starting treatment at a low dose, for example amitriptyline 5–10 mg at night, and titrating the dose up in steps of 10 mg at least every 2 weeks if needed, to a maximum of 30 mg at night.</li></ul></li><li><strong>Selective serotonin reuptake inhibitors (SSRIs) such as citalopram or fluoxetine</strong> are second-line drug options (off-label indication). Possible treatment doses are:<ul><li>Citalopram — 10–20 mg daily.</li><li>Fluoxetine — 20 mg daily.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">NICE, 2017</a>]</p><!-- end field 612e617f-3888-4753-8300-a800010645b9 --><!-- end item 1ec4edc6-6442-4846-b914-44faea628178 -->","topic":{"id":"4bb8acbd-d2b1-5f93-9ffa-0a3f11076292","topicId":"2c2fedc7-3daf-462e-b168-78c86cb2a2ec","topicName":"Irritable bowel syndrome","slug":"irritable-bowel-syndrome","lastRevised":"Last revised in October 2020","chapters":[{"id":"e08d84ab-7283-58cb-9873-bebac62d6494","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"09b06ced-d018-5c24-883c-ff37be197b2d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"14d879ef-e87a-571a-a829-4f236e5265b8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0858c465-429d-5390-b8bd-432cb1d0fb46","slug":"changes","fullItemName":"Changes"},{"id":"fbcab9c4-bcb5-5d61-855f-1ec3aef8fdfe","slug":"update","fullItemName":"Update"}]},{"id":"d1d333cb-5ad0-5c55-987c-0d9bcdd7219b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"df8485dd-d258-554e-91a1-cfae144c8f3a","slug":"goals","fullItemName":"Goals"},{"id":"92f70986-7a29-5aaf-8c2b-e24b675e84dc","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4cbbe159-85f5-573d-a6f1-cf83b24c7513","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b054d7f7-3303-57ad-bc98-df229e629e9c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d5eb318d-cbd0-556b-8ce7-6c20aab02bc0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c7ecf3c9-b183-5b40-99b8-9fa4ac12bfb8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"156f0f16-df4f-5fcf-94da-2e9dfe0d9ae7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d091ffcd-a585-5def-b8a6-6a8e82be964d","slug":"definition","fullItemName":"Definition"},{"id":"08e0e6c7-a53c-53d9-a8ff-37b9af0475a9","slug":"causes","fullItemName":"Causes"},{"id":"2af080fe-338c-5682-927e-df91b2056310","slug":"prevalence","fullItemName":"Prevalence"},{"id":"668a8344-5367-57b6-be24-4904a8b84c09","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"d71af51f-0d21-583c-ae74-cdeefe5efe9a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1e13d165-63d9-5000-8411-3cb047828b3a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"d335e933-3ba3-56d3-9f86-ccb100e2cb09","slug":"assessment","fullItemName":"Assessment"},{"id":"f6a63ea2-fb31-5f4c-b6ca-21ee922d5615","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"a0f45b9c-efa3-5c88-a5bc-3cd26c71883f","fullItemName":"Management","slug":"management","subChapters":[{"id":"d4748fe8-65f9-5b0b-bbd0-32469fde1c78","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"86d862ff-43f3-59ac-9769-c4bc0ec5ea9b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4517eb7c-ad75-5732-86b2-ea7cf18e7a93","slug":"bulk-forming-laxatives","fullItemName":"Bulk-forming laxatives"},{"id":"712646a9-5a89-5454-b98e-b2d2dce9ac3d","slug":"linaclotide","fullItemName":"Linaclotide"},{"id":"b36ea15d-0d7e-5080-9c77-f7f1b274523b","slug":"loperamide","fullItemName":"Loperamide"},{"id":"c7ea4d4a-3d5a-5cdb-8999-e01670699563","slug":"antispasmodic-drugs","fullItemName":"Antispasmodic drugs"},{"id":"b5eff265-676e-584f-a5d6-0a4714238d8f","slug":"antidepressant-drugs","fullItemName":"Antidepressant drugs"}]},{"id":"2c06aa30-84a6-5e94-8d6f-1d960d28dcdc","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"25c14e40-3957-5b26-aa34-0afc73225fdd","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"38e74c6b-daec-50bd-a23a-3aa30b83db82","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c6497438-25eb-590a-9d9d-dfe08a17fb21","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"36885cba-cf5e-5cab-a474-2c0fc504fa91","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"89b5e4f9-0ed1-5b13-8258-3ba2b6f5b43e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d3199940-6be9-57b4-a2b0-2ee240db6d97","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5667ce2f-151b-57f5-9fde-07b6339b1aef","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"86d862ff-43f3-59ac-9769-c4bc0ec5ea9b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a4185a30-e62c-5fc8-b5ce-bbf5ea71d3a3","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 29baf8bb-23af-4de5-84a9-29e00eb4be76 --><h3>Contraindications and cautions</h3><!-- end field 29baf8bb-23af-4de5-84a9-29e00eb4be76 -->","summary":"","htmlStringContent":"<!-- begin item 905884df-5939-4017-b770-48afc4b899ea --><!-- begin field a60ed33a-6734-4ed3-8e4e-b88e2a5587f5 --><p><strong>Do not prescribe amitriptyline to people with:</strong></p><ul><li>Acute porphyrias.</li><li>Arrhythmias or heart block.</li><li>During manic phase of bipolar disorder.</li><li>Immediate recovery period following myocardial infarction.</li><li>Severe liver disease — sedative effects are increased in hepatic impairment.</li></ul><p><strong>Prescribe amitriptyline with caution in people with:</strong></p><ul><li>Cardiovascular disease.</li><li>Chronic constipation.</li><li>Diabetes mellitus; epilepsy.</li><li>History of bipolar disorder or psychosis (treatment should be stopped if the person enters a manic phase); a significant risk of suicide.</li><li>Hyperthyroidism or phaeochromocytoma (risk of arrhythmias).</li><li>Increased intraocular pressure or susceptibility to angle-closure glaucoma.</li><li>Prostatic hypertrophy or urinary retention.</li></ul><p><strong>Do not prescribe selective serotonin reuptake inhibitors (SSRIs) to people with:</strong></p><ul><li>Poorly controlled epilepsy.</li><li>QT interval prolongation (citalopram only).</li></ul><p><strong>Prescribe SSRIs with caution in people with:</strong></p><ul><li>History of bipolar disorder or psychosis (treatment should be stopped if the person enters a manic phase).</li><li>Cardiac disease.</li><li>Concurrent electroconvulsive therapy.</li><li>Diabetes mellitus.</li><li>Epilepsy — stop treatment if seizures develop.</li><li>History of bleeding disorders, especially gastrointestinal bleeding.</li><li>Susceptibility to angle-closure glaucoma.</li><li>Susceptibility to QT interval prolongation (citalopram only).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">BNF 73, 2017</a>]</p><!-- end field a60ed33a-6734-4ed3-8e4e-b88e2a5587f5 --><!-- end item 905884df-5939-4017-b770-48afc4b899ea -->","subChapters":[]},{"id":"f52ecaa1-a607-5875-9a04-a7339764f0f3","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 440b63c2-1d41-499f-9139-b28c1b715dc0 --><h3>Adverse effects</h3><!-- end field 440b63c2-1d41-499f-9139-b28c1b715dc0 -->","summary":"","htmlStringContent":"<!-- begin item 49ee7668-5ac8-4f05-a2a1-be6fcd192815 --><!-- begin field 9afacf78-6002-4d0f-80fd-5e4eac55a544 --><p><strong>Possible adverse effects of amitriptyline include:</strong></p><ul><li>Abdominal pain, fatigue, hypertension, mydriasis, oedema, palpitations, restlessness, stomatitis.</li><li>Dysarthria, extrapyramidal symptoms, tremor, paralytic ileus.</li></ul><p><strong>Possible adverse effects of selective serotonin reuptake inhibitors (SSRIs) include:</strong></p><ul><li>Abdominal pain, constipation, diarrhoea, dyspepsia, nausea and vomiting (all dose-related effects).</li><li>Serotonin syndrome, angle-closure glaucoma (rare).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/irritable-bowel-syndrome/references/\">BNF 73, 2017</a>]</p><!-- end field 9afacf78-6002-4d0f-80fd-5e4eac55a544 --><!-- end item 49ee7668-5ac8-4f05-a2a1-be6fcd192815 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}